Avalo Therapeutics Inc
Avalo Therapeutics Inc (AVTX) Historical Volatility
AVTX's 30 day historical volatility is 167.01%, in the 99th percentile of readings over the past year. This is a high percentile, meaning Avalo Therapeutics Inc shares have swung far more than usual. AVTX's 30 day implied volatility sits at 85.16%, with an IV Rank of 12.70%, leaving IV 81.85 points below historical volatility. This means options are pricing in less movement than the stock has actually delivered, as of Nov 18, 2026.
Read more
Tracking AVTX historical volatility helps you see how much Avalo Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, AVTX's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor AVTX 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. AVTX's 30 day historical volatility, or AVTX HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing AVTX's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 18, 2026
As of Nov 18, 2026
As of Nov 18, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →